Evofem Biosciences, Inc. et al. v. Padagis Israel Pharmaceuticals, Ltd. et al.
Infringement action filed 1 Jun 2023 in the United States District Court for the District of New Jersey and closed 22 Sep 2023, with 3 patents asserted. Recorded basis of termination: dismissed without prejudice.
Case record
- Patents involved
- US10568855B2US11439610B2US11337989B2
- Case no.
- 3:23-cv-03003
- Verdict cause
- Infringement action
- Court
- D.N.J.
- Court level
- District Court
- Case region
- New Jersey
- Chief judge
- None recorded
- Trial level
- First instance
- Filed – Closed
- 1 Jun 2023 – 22 Sep 2023
- Duration
- 113 days
- Basis of termination
- Dismissed without Prejudice
- Products & marks
- Compositions and methods for enhancing the efficacy of contraceptive microbicides · Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Compositions and methods for enhancing the efficacy of contraceptive microbicides
The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to syngergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.
- Legal status
- Active
- Granted
- 25 Feb 2020
- Earliest priority
- 15 Mar 2013
- Est. expiry
- 15 Mar 2033
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- GUTHRIE, WENDELL
- Classification
- A61K31/19A61K9/00A61K31/675A61K9/06A61K47/36A61K47/12A61K47/10
- Prosecution counsel
- PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
- Examiner
- WORSHAM, JESSICA
Compositions and methods for enhancing the efficacy of contraceptive microbicides
The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to synergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.
- Legal status
- Active
- Granted
- 13 Sep 2022
- Earliest priority
- 13 Jun 2012
- Est. expiry
- 15 Mar 2033
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- GUTHRIE, WENDELL
- Classification
- A61K31/19A61K47/12A61K47/36A61K9/00A61K31/675A61K9/06A61K47/10
- Prosecution counsel
- PROCOPIO, CORY, HARGREAVES & SAVITCH LLP
- Examiner
- WORSHAM, JESSICA
Also asserted in this case
1 moreThe docket lists 3 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining asserted patent are one query away in Eureka.
Parties of record
Evofem Biosciences, Inc.
- Core tech
- A61K31/19A61K9/00A61K31/675A61K9/06
- Counsel
- Charles H. Chevalier
- Firm
- Gibbons PC
- Also named
- Evofem Biosciences Operations, Inc. · Evofem, Inc.
Padagis Israel Pharmaceuticals, Ltd.
- Core tech
- Not recorded
- Counsel
- Rebekah R. Conroy
- Firm
- Stone Conroy LLC
- Also named
- Padagis, LLC · Padagis US, LLC
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Charles H. Chevalier | Evofem Biosciences, Inc. | Plaintiff |
| Rebekah R. Conroy | Padagis Israel Pharmaceuticals, Ltd. | Defendant |
Basis of termination
From the record · verbatim“NOW THEREFORE, it is hereby stipulated and agreed as follows: 1. All claims, counterclaims, and defenses between Plaintiffs and Padagis relating to the Asserted Patents are hereby voluntarily dismissed without prejudice pursuant to Fed. R. Civ. 41(a)(1)(A)(ii) and 41(c). 2. Each party shall bear its own costs and attorneys’ fees with respect to any claim, counterclaim, or defense relating to the Asserted Patents.”
Case 3:23-cv-03003 · D.N.J. · closed 22 September 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 3:23-cv-03003?
3:23-cv-03003 is a patent infringement action brought by Evofem Biosciences, Inc. against Padagis Israel Pharmaceuticals, Ltd., filed on 1 Jun 2023 in the United States District Court for the District of New Jersey. The case closed on 22 September 2023.
Which patents were asserted in 3:23-cv-03003?
US10568855B2 (“Compositions and methods for enhancing the efficacy of contraceptive microbicides”), assigned to EVOFEM, INC., currently active; US11439610B2 (“Compositions and methods for enhancing the efficacy of contraceptive microbicides”), assigned to EVOFEM, INC., currently active; US11337989B2 (“Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound”), assigned to EVOFEM, INC.. The record also lists Compositions and methods for enhancing the efficacy of contraceptive microbicides and Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound.
How was case 3:23-cv-03003 terminated?
The recorded basis of termination is dismissed without prejudice. The termination text reads: “NOW THEREFORE, it is hereby stipulated and agreed as follows: 1. All claims, counterclaims, and defenses between Plaintiffs and Padagis relating to the Asserted Patents are hereby voluntarily dismissed without prejudice pursuant to Fed. R. Civ. 41(a)(1)(A)(ii) and 41(c). 2. Each party shall bear its own costs and attorneys’ fees with respect to any claim, counterclaim, or defense relating to the Asserted Patents.”
What does dismissal without prejudice mean?
A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.
How long did case 3:23-cv-03003 take?
113 calendar days, from filing on 1 Jun 2023 to closure on 22 September 2023.
Who were the attorneys and the judge in 3:23-cv-03003?
Charles H. Chevalier is recorded as counsel for plaintiff Evofem Biosciences. Rebekah R. Conroy appears for defendant Padagis Israel Pharmaceuticals.
Disclaimer. This page reproduces publicly available court docket data for case 3:23-cv-03003 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.